{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:28Z","timestamp":1793394088384,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.blre.2025.101300","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:14:25Z","timestamp":1746818065000},"page":"101300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments"],"prefix":"10.1016","volume":"73","author":[{"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101300_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s44337-024-00040-8","article-title":"Immune thrombocytopenia: a review of pathogenesis and current treatment","volume":"1","author":"Yan","year":"2024","journal-title":"Discov Med"},{"key":"10.1016\/j.blre.2025.101300_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s44337-024-00008-8","article-title":"Immune thrombocytopenia (ITP): historical perspectives, pathophysiology, and treatment advances","volume":"1","author":"Tungjitviboonkun","year":"2024","journal-title":"Discov Med"},{"key":"10.1016\/j.blre.2025.101300_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101222","article-title":"Immune thrombocytopenia: pathophysiology and impacts of Romiplostim treatment","volume":"67","author":"Semple","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101300_bb0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/hematolrep16020021","article-title":"Pathophysiology, clinical manifestations and diagnosis of immune thrombocytopenia: contextualization from a historical perspective","volume":"16","author":"Mart\u00ednez-Carballeira","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.blre.2025.101300_bb0025","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101300_bb0030","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101300_bb0035","first-page":"6","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101300_bb0040","first-page":"12","article-title":"Recommendations for the clinical approach to immune thrombocytopenia: Spanish ITP working group (GEPTI)","author":"Mingot-Castellano","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101300_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0050","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12185-020-02977-9","article-title":"High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study","volume":"112","author":"Ma","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0055","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101300_bb0060","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2012.13593","article-title":"Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review","volume":"142","author":"Imbach","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.blre.2025.101300_bb0065","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2016-04-710285","article-title":"Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy","volume":"128","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2015-05-647552","article-title":"Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy","volume":"127","author":"Ammann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2025.101300_bb0085","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","article-title":"Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature","volume":"66","author":"Lidar","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.blre.2025.101300_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study","volume":"12","author":"Peng","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101300_bb0095","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2141.2003.04509.x","article-title":"The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb\/IIIa in patients with idiopathic thrombocytopenic purpura","volume":"122","author":"Chan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0100","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101300_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Qin","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2025.101300_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/08916934.2015.1104671","article-title":"Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: results of a prospective study including 167 cases","volume":"49","author":"Zhou","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.blre.2025.101300_bb0115","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","article-title":"Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients","volume":"95","author":"Gaines","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0120","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.blre.2025.101300_bb0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"McMillan","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.2010.08322.x","article-title":"Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP)","volume":"151","author":"Sarpatwari","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0135","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2025.101300_bb0140","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2025.101300_bb0145","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2025.101300_bb0150","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.blre.2025.101300_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101300_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102231","article-title":"Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"7","author":"Xia","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101300_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2025.101300_bb0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101300_bb0190","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"9-18","author":"Kuter","year":"2008","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.blre.2025.101300_bb0195","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0200","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0205","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.27131","article-title":"Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial","volume":"99","author":"Cooper","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed Rep"},{"key":"10.1016\/j.blre.2025.101300_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0230","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101300_bb0235","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0240","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0245","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0250","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2025.101300_bb0255","unstructured":"European Medicines Agency. Tavlesse. Available in: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/Tavlesse."},{"key":"10.1016\/j.blre.2025.101300_bb0260","first-page":"S347","article-title":"Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia","volume":"25","author":"McBride","year":"2019","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.blre.2025.101300_bb0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/imt-2017-0097","article-title":"Fostamatinib for persistent\/chronic adult immune thrombocytopenia","volume":"10","author":"Newland","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.blre.2025.101300_bb0270","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0275","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.48215","article-title":"Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial","volume":"7","author":"Collins","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2025.101300_bb0280","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0285","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/jha2.939","article-title":"Fostamatinib for immune thrombocytopenic purpura in adult patients: a systematic review and meta-analysis","volume":"5","author":"Kou","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.blre.2025.101300_bb0290","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2024024250","article-title":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","volume":"144","author":"Gonz\u00e1lez-L\u00f3pez","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0295","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.blre.2025.101300_bb0300","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0305","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2025.101300_bb0315","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/09537104.2019.1624706","article-title":"The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2025.101300_bb0320","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0325","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101300_bb0330","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.13029","article-title":"A multi-Centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)","volume":"167","author":"Tran","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0335","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0340","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0345","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0350","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0355","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0360","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-023-06820-4","article-title":"Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis","volume":"43","author":"Abdelwahab","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.blre.2025.101300_bb0365","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate Mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101300_bb0370","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221149870","article-title":"Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"51","author":"Li","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.blre.2025.101300_bb0375","first-page":"217","article-title":"Safety and efficacy of azathioprine in immune thrombocytopenia","volume":"11","author":"Mishra","year":"2021","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.blre.2025.101300_bb0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.15090","article-title":"A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP","volume":"181","author":"Rodeghiero","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0385","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0395","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.26378","article-title":"Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment","volume":"97","author":"Mageau","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0400","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ejh.12146","article-title":"Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia","volume":"91","author":"Gonzalez-Porras","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0405","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199705223362104","article-title":"High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura","volume":"336","author":"Law","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101300_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103040","article-title":"Autologous platelet scintigraphy and clinical outcome of splenectomy in immune thrombocytopenia: a systematic review and meta-analysis","volume":"153","author":"Amini","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0415","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjsurg.2003.11.032","article-title":"Laparoscopic splenectomy for idiopathic thrombocytopenic purpura","volume":"187","author":"Wu","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.blre.2025.101300_bb0420","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.20433","article-title":"Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count","volume":"80","author":"Keidar","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0425","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-018-3232-x","article-title":"Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia","volume":"97","author":"Togasaki","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0430","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.blre.2025.101300_bb0435","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101300_bb0445","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.179.7.4580","article-title":"Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism","volume":"179","author":"Akilesh","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0450","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.blre.2025.101300_bb0455","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.blre.2025.101300_bb0460","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101300_bb0465","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2025.101300_bb0470","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101300_bb0475","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0480","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton\u2019s tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0485","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.39657","article-title":"Bruton\u2019s tyrosine kinase deficiency inhibits autoimmune arthritis in mice but fails to block immune complex-mediated inflammatory arthritis","volume":"68","author":"Nyhoff","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.blre.2025.101300_bb0490","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2025.101300_bb0495","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0500","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an Oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101300_bb0505","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/bloodadvances.2023012044","article-title":"Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia","volume":"8","author":"Kuter","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101300_bb0510","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"Kuter","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101300_bb0515","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clim.2017.12.010","article-title":"Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP)","volume":"188","author":"Kamhieh-Milz","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0520","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1182\/blood-2009-10-247536","article-title":"ITP has elevated BAFF expression","volume":"114","author":"Semple","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0525","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101300_bb0530","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2025.101300_bb0535","doi-asserted-by":"crossref","first-page":"e29155a4","DOI":"10.1097\/01.HS9.0000977232.29155.a4","article-title":"PB2636: VAYHIT1: a multicenter, randomized, double-blind, phase III trial of IANALUMAB versus placebo in addition to first-line corticosteroids in patients with primary immune thrombocytopenia (ITP)","volume":"7","author":"Cooper","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2025.101300_bb0540","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000977188.95345.32","article-title":"PB2625: VAYHIT2: a randomized, double- blind, phase III trial of IANALUMAB vs placebo in addition to Eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed FIRST-line steroid treatment","volume":"7","author":"Zaja","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2025.101300_bb0545","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1182\/blood-2023-180005","article-title":"VAYHIT3: an open-label, single-arm, phase II trial to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least 1 corticosteroid and 1 thrombopoietin receptor agonist (TPO-RA)","volume":"142","author":"Kuter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0550","first-page":"11","article-title":"P104. Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-fc; ALPN-303)","author":"Katherine","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.blre.2025.101300_bb0555","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1182\/blood-2023-179305","article-title":"Initial report of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoimmune cytopenias: the RUBY-4 study","volume":"142","author":"Broome","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0560","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103289","article-title":"The potential of CD38 protein as a target for autoimmune diseases","volume":"22","author":"Ye","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2025.101300_bb0570","first-page":"1","article-title":"Antibody-drug conjugate therapies in multiple myeloma-what\u2019s next on the horizon?","volume":"3","author":"Hartley-Brown","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.blre.2025.101300_bb0575","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1182\/blood-2021-151410","article-title":"Daratumumab as a treatment for adult immune thrombocytopenia: a phase II study with safety run-in (the DART study)","volume":"138","author":"Tsykunova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101300_bb0580","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2025.101300_bb0585","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101300_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101300_bb0595","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cei\/uxac096","article-title":"A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models","volume":"211","author":"Cho","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2025.101300_bb0600","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T14:26:49Z","timestamp":1755959209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":120,"alternative-id":["S0268960X25000451"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101300","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101300"}}